These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28363735)

  • 1. Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
    Cox S; Margot N; Ram R; Johnson A; Miller M; Callebaut C
    Antiviral Res; 2017 Jul; 143():22-29. PubMed ID: 28363735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
    Margot N; Ram R; Abram M; Haubrich R; Callebaut C
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
    Margot NA; Johnson A; Miller MD; Callebaut C
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
    Margot NA; Liu Y; Miller MD; Callebaut C
    Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    Cox S; Margot N; Callebaut C
    J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
    Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
    J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.
    Cox S; Margot N; Miller M; Callebaut C
    AIDS Res Hum Retroviruses; 2018 May; 34(5):456-458. PubMed ID: 29620930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
    Birkus G; Bam RA; Willkom M; Frey CR; Tsai L; Stray KM; Yant SR; Cihlar T
    Antimicrob Agents Chemother; 2016 Jan; 60(1):316-22. PubMed ID: 26503655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
    Margot NA; Waters JM; Miller MD
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
    Liu Y; Miller MD; Kitrinos KM
    Antiviral Res; 2017 Mar; 139():25-31. PubMed ID: 28017761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
    Ma B; Barth A; McHale CM; Lai MT
    Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
    Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
    Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
    Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
    J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
    Chan PA; Huang A; Kantor R
    J Int AIDS Soc; 2012 Oct; 15(2):17701. PubMed ID: 23305651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficient vaginal transmission of tenofovir-resistant HIV-1.
    Chateau M; Swanson MD; Garcia JV
    J Virol; 2013 Jan; 87(2):1274-7. PubMed ID: 23115295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.